Ming-Ming Zhou

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ming-Ming Zhou, Ph.D.
Fields structural and chemical biology
Institutions Mount Sinai Medical Center
Alma mater East China University of Science and Technology
Michigan Technological University
Purdue University

Ming-Ming Zhou, Ph.D., is an internationally recognized expert in structural and chemical biology, NMR spectroscopy of protein structure-function and rational small-molecule design.[1] He is currently the Dr. Harold and Golden Lamport Professor and Chairman of the Department of Pharmacological Sciences and Co-Director of the Experimental Therapeutics Institute at the Mount Sinai School of Medicine at the Mount Sinai Medical Center in New York City as well as Professor Oncological Sciences.[2]

Zhou has published more than 110 peer-reviewed research articles and has received multiple grants from federal, state and private research foundations including the National Institutes of Health, the National Science Foundation, the New York State Stem Cell Science (NYSTEM), the Institute for the Study of Aging, the American Foundation for AIDS Research, the American Cancer Society, GlaxoSmithKline, the Michael J. Fox Foundation, and the Wellcome Trust. He serves on the editorial boards of ACS Medicinal Chemistry Letters, the Journal of Molecular Cell Biology[3] and Cancer Research.[4] He has been awarded 5 patents.

Biography[edit]

Zhou earned his B.S. in Chemical Engineering from the East China University of Science and Technology (Shanghai, PRC) in 1984. He earned his M.S. in Chemistry from the Michigan Technological University in 1988 and a Ph.D. in Chemistry from Purdue University in Indiana in 1993. He completed his postdoctoral fellowship at Abbott Laboratories in Chicago, Illinois, then joined the Mount Sinai Medical Center in 1997.

Zhou’s research is directed at understanding the fundamental molecular mechanisms that govern cellular signal transduction and epigenetic control of gene transcription in human biology of health and disease by using combined structural/chemical biology and molecular/cell biology approaches. His research contributions include the discovery of the bromodomain as the acetyl-lysine binding domain in epigenetic gene regulation,[5] the tandem PHD finger of DPF3b as a first alternative to the bromodomain for acetyl-lysine binding,[6] and the PAZ domain as the RNA binding domain in RNAi.[7] His recent work also addresses the role of histone lysine methylation (Nature Cell Biol. 2008)[8] as well as long non-coding RNA in epigenetic control of gene transcription in human stem cell maintenance and differentiation.[9]

Zhou's work in rational design of chemical probes for mechanism-driven research led to the discovery of the HIV Tat/human co-activator PCAF interaction as a potential novel anti-HIV therapy target.[10] His group has also developed chemical probes that modulate the transcriptional activity of human tumor suppressor p53 under stress conditions. His recent work includes the development of a novel gene transcriptional silencing technology.

The current focuses of his laboratory include the roles of the Trithorax protein complexes and the Polycomb repressive complexes in gene activation and silencing in human biology of health and disease such as stem cell self-renewal and lineage commitment, cancer and inflammation.[11] Additional research interests include the structure and mechanisms of epigenetic gene regulation and chromatin biology, structure-based small molecule design, mechanism-based disease biology and drug discovery in HIV/AIDS, human cancer, leukemia and inflammation, neurodegenerative disorders including multiple sclerosis, Parkinson’s and Alzheimer's disease.

Current and past society memberships include The Harvey Society, the Biophysical Society,[12] the American Chemical Society, the American Society for Biochemistry and Molecular Biology, the American Association for the Advancement of Science and the New York Academy of Sciences. He serves on multiple editorial boards and reviews grants for the American Cancer Society, the American Heart Association, the National Institutes of Health and the National Science Foundation.

Awards and honors[edit]

  • 2009 Elected to the Academy of Sciences & Arts at Michigan Technological University[13]
  • 2006 Dr. Harold and Golden Lamport Professorship in Physiology and Biophysics
  • 2003 GlaxoSmithKlineDrug Discovery and Development Award[14]
  • 1999 American Cancer Society Young Investigator Award

Patents[edit]

Title Number
“Methods of Identifying Modulators of the FGF Receptors” 20060019296[15]
“Methods of Identifying Modulators of Bromodomains” 7,589,167[16]
“Methods and Compositions for the Treatment of Disorders of HIV Infection” USSN10/413,785 pending
“Small-Molecular Chemicals That Inhibit HIV Tat Interactions with Human PCAF in Viral

Transcriptional Activation”

US Provisional PA, pending.
“Method of Suppressing Gene Transcription Through Histone Lysine Methylation” US Provisional PA Serial No. 61/041,363, pending

Publications[edit]

Partial list:

References[edit]

  1. ^ "The Michael J. Fox Foundation for Parkinson's Research". Retrieved March 8, 2011. 
  2. ^ "Mount Sinai School of Medicine - Ming-Ming Zhou". Retrieved March 8, 2011. 
  3. ^ "Journal of Molecular Cell Biology - Editorial Board". Retrieved March 8, 2011. 
  4. ^ "Cancer Research: Editorial Board". Retrieved March 8, 2011. 
  5. ^ Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM (June 1999). "Structure and ligand of a histone acetyltransferase bromodomain". Nature. 399 (6735): 491–6. doi:10.1038/20974. PMID 10365964. 
  6. ^ Zeng L, Zhang Q, Li S, Plotnikov AN, Walsh MJ, Zhou MM (July 2010). "Mechanism and regulation of acetylated histone binding by the tandem PHD finger of DPF3b". Nature. 466 (7303): 258–62. doi:10.1038/nature09139. PMC 2901902Freely accessible. PMID 20613843. 
  7. ^ Yan KS, Yan S, Farooq A, Han A, Zeng L, Zhou MM (November 2003). "Structure and conserved RNA binding of the PAZ domain". Nature. 426 (6965): 468–74. doi:10.1038/nature02129. PMID 14615802. 
  8. ^ Mujtaba S, Manzur KL, Gurnon JR, Kang M, Van Etten JL, Zhou MM (August 2008). "Epigenetic transcriptional repression of cellular genes by a viral SET protein". Nat. Cell Biol. 10 (9): 1114–1122. doi:10.1038/ncb1772. PMC 2898185Freely accessible. PMID 19160493. 
  9. ^ Yap KL, Li S, Muñoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, Gil J, Walsh MJ, Zhou MM (June 2010). "Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a". Mol. Cell. 38 (5): 662–74. doi:10.1016/j.molcel.2010.03.021. PMC 2886305Freely accessible. PMID 20541999. 
  10. ^ Zeng L, Li J, Muller M, Yan S, Mujtaba S, Pan C, Wang Z, Zhou MM (March 2005). "Selective small molecules blocking HIV-1 Tat and coactivator PCAF association". J. Am. Chem. Soc. 127 (8): 2376–7. doi:10.1021/ja044885g. PMID 15724976. 
  11. ^ "Mount Sinai researchers discover technology that silences genes". Retrieved March 8, 2011. 
  12. ^ "Biophysical Society". Retrieved March 8, 2011. 
  13. ^ "Michigan Technological University - College of Sciences and Arts". Retrieved March 8, 2011. 
  14. ^ "GlaxoSmithKline Drug Discovery and Development Research Grant Program 2003". Retrieved March 8, 2011. 
  15. ^ "Methods of identifying modulators of the FGF receptor - US Patent Application". Retrieved March 8, 2011. 
  16. ^ "US Patent & Trademark Office". Retrieved March 8, 2011. 

External links[edit]